Download presentation
1
Meniere’s Disease Dr. Vishal Sharma
2
Introduction Described by Prosper Meniere in 1861
Vertigo + Deafness + Tinnitus + Aural fullness Etiology: endolymphatic hydrops (Hallpike, 1938) due to ed absorption of endolymph or ed production of endolymph Especially involves cochlear duct & saccule
3
Prosper Meniere`
4
Normal membranous labyrinth
5
Endolymphatic Hydrops
6
Normal membranous labyrinth
7
Endolymphatic Hydrops
8
Pathogenesis
9
1. Endolymphatic hydrops rupture of membranous labyrinth potassium rich endolymph mixes with perilymph sustained inactivation of hair cells & neurons of vestibulo-cochlear nerve bathed in perilymph deafness + vertigo + tinnitus 2. ed Sympathetic activity ischemia of cochlear & vestibular end organs deafness + vertigo
10
Etiology of Primary Meniere’s disease
11
B. Increased production of endolymph: Allergy
A. Idiopathic B. Increased production of endolymph: Allergy Sodium & water retention Autoimmune Viral infection sympathetic activity ischemia of stria vascularis fluid transudation
12
Endocrine Hypo (thyroidism, pituitarism,
adrenalism), Diabetes, Hyperlipoproteinemia C. Decreased absorption of endolymph: Small size of endolymphatic sac / duct Obstruction of endolymphatic sac / duct Ischaemia of endolymphatic sac Inner ear trauma
13
Secondary Meniere Syndrome
Clinically resembles Meniere’s disease. Seen in: Syphilis Otosclerosis, Cogan syndrome (interstitial keratitis) Post-stapedectomy Paget’s disease
14
Clinical Features years, more in males, unilateral 1. Vertigo: Sudden onset, episodic, rotatory, 30 min - 24 hr, along with nausea, vomiting & diaphoresis % pt have positional vertigo Vertigo caused by loud, low frequency sound Tulio phenomenon
15
Clinical Features 2. Deafness: Accompanies vertigo, improves after vertigo attack, sensori-neural, fluctuant, progressive Intolerance to loud sound (due to recruitment) Distortion of sound frequency, called diplacusis binauralis dysharmonica
16
Clinical Features 3. Tinnitus: Low-pitch, roaring, non-pulsatile, continuous / intermittent. Increased during vertigo attacks 4. Aural fullness: Fluctuating, not relieved by swallowing 5. Emotional upset, anxiety, agoraphobia
17
AAO-HNS Diagnosis Criteria (1995)
A. Vertigo: Spontaneous, > 2 episodes lasting > 20 min B. Audiogram documented sensori-neural deafness C. Tinnitus or Aural fullness in diseased ear D. Other cases excluded E. Staging as per pure tone average ( Hz): 1 = < 25 dB 2 = dB 3 = dB 4 = > 70 dB
18
Meniere’s disease variants
19
Lermoyez’s reverse Meniere syndrome: Deafness vertigo improvement in hearing
Tumarkin’s sudden drop attack: Pt falls without vertigo / loss of consciousness Meyerhoff’s oculo-vestibular response: Vertigo due to opto-kinetic stimulus Cochlear hydrops: deafness & tinnitus only Vestibular hydrops: vertigo only
20
E.N.T. Examination Otoscopy: normal tympanic membrane
Nystagmus: irritative paralytic recovery False +ve fistula sign (Hennebert sign): in 30% pt Rinne test: positive (A.C. > B.C.) Weber test: lateralizes towards better ear A.B.C. test: decreased in diseased ear
21
Irritative nystagmus: occurs immediately with onset of an attack, for 20 seconds, toward diseased ear, due to initial excitation of action potential by increasing potassium in perilymph Paralytic nystagmus: occurs minutes into an attack, toward healthy ear, due to blockade of action potential by increased K+ in perilymph Recovery nystagmus: occurs hours later, toward diseased ear, due to vestibular adaptation
22
Pure Tone Audiometry
23
Rising curve in early stage
Low frequency SNHL due to more fluid accumulation in apical portion of scala media
24
Low + high frequency sensori-neural deafness
Inverted curve Low + high frequency sensori-neural deafness
25
Uniform sensori-neural deafness
Flat curve Uniform sensori-neural deafness
26
Further SNHL in high frequency
Down sloping curve Further SNHL in high frequency
27
Other Audiological Tests
Speech Audiometry: Score = % A.B.L.B.: Recruitment present S.I.S.I.: positive (> 70 % score) Tone Decay Test: negative (decay < 20 dB)
28
Laddergram in A.B.L.B.
29
Electro-cochleography
30
Electro-cochleography findings in Meniere’s disease
Summation potential : compound action potential ratio > 30 % Widened SP-AP waveform (> 2msec) Distorted cochlear micro-phonics
31
SP – AP Waveform
32
Cochlear Microphonics
SP/AP > 30 % Normal Distorted CM
33
Bithermal Caloric Test
I/L canal paresis in 75 % cases
34
Bithermal Caloric Test
C/L directional preponderance
35
Glycerol Test (confirmatory)
Do P.T.A. & speech audiogram. Glycerol (1.5 ml / Kg), mixed in lime juice given orally. Repeat audio tests after 2 hrs. Test is positive if: Pure Tone threshold improves > 10 dB Speech Discrimination Score increases > 15 % S.P. / A.P. ratio in E.Co.G. decreases > 15 %
36
Other Investigations Full blood count + ESR Urea, electrolytes
RBS, FBS Fasting lipid profile Thyroid function test VDRL, TPHA Immunological assay, antibody screening
37
Treatment of Acute attack
Reassurance Bed rest + head support Inj. Prochlorperazine (Stemetil): 12.5 mg I.V., T.I.D. – Q.I.D. Inj. Promethazine (Phenergan): 25 mg I.V., T.I.D. – Q.I.D. Inj. Diazepam (Calmpose): 5 mg I.V. stat
38
Non-surgical treatment
Discussion: Reassurance. Avoid tea, coffee, colas, chocolate, allergens, stress, smoking, alcohol, flying, diving, heights. Diet: Low salt (1.5 g/day), less fluids. Exercise. Vestibular Depressants: Cinnarizine, Diazepam, Prochlorperazine, Dimenhydrinate
39
Non-surgical treatment
Cochlear VasoDilators: Betahistine, Xanthinol nicotinate, Carbogen (5 % CO % O2), L.M.W. Dextran, Histamine drip. Diuretics: Thiazide + Triamterene Dexamethasone / Ig G: decreases auto-immunity Dehydration by hyperosmolar fluids Hormone replacement therapy
40
Meniett Device Low pressure pulse generator. Pressure pulses transmitted to round window via grommet displace endolymph relieve endolymph hydrops. Used for 5 min, TID.
41
Meniett Device
42
Surgical treatment of Meniere’s disease
43
A. Hearing preservation + Balance preservation:
1. Endolymphatic sac decompression / shunting 2. Sacculotomy by puncture of footplate 3. Cochlear duct piercing via round window B. Hearing preservation + Balance ablation: 1. Chemical labyrinthectomy Vestibular neurectomy 3. Vestibular end organ destruction by USG / cryoprobe C. Hearing ablation + Balance ablation: 1. Section of 8th nerve Total labyrinthectomy
44
Decompression Surgery
1. Endolymphatic sac decompression (Portmann) 2. Endolymphatic sac shunting: into sub- arachnoid space or mastoid cavity 3. Sacculotomy: Fick’s needle puncture of footplate Cody’s tack puncture of footplate 4. Cochlear duct piercing via round window
45
Decompression Surgery
46
Endolymphatic sac decompression
47
Georges Portmann
48
Sac shunting into mastoid
49
Sac shunting into subarachnoid
50
Fick’s needle puncture of footplate
51
Chemical Labyrinthectomy
Trans-tympanic drug injection Intra-tympanic drug instillation via grommet Intra-tympanic drug instillation via Silverstein micro wick Trans-tympanic drug perfusion Drug used: Gentamicin (vestibulo-toxic)
52
Trans-tympanic injection
53
Intra-tympanic drug instillation
54
Grommet in P.I.Q.
55
Trans-tympanic gentamicin
26.7 mg/ml solution used 0.75 ml solution instilled in affected ear (via grommet) 3 times daily for 4 consecutive days After instillation, pt to lie supine with affected ear up for 30 min & not swallow anything Vertigo control = 94%. Hearing unchanged or improved = 74%. Hearing worsened = 26%.
56
Silverstein micro wick
57
Trans-tympanic drug perfusion
58
Trans-tympanic Dexamethasone
Mechanism of action: reducing inflammation control of auto-immune injury Solution strength: 0.25 mg/ml Dose: 5 drops every alternate day for 3 months
59
Vestibular Surgery Denervation of vestibule by vestibular neurectomy via middle cranial fossa Destruction of vestibule (via round window or lateral semicircular canal) by: Cryo-probe Ultrasound probe
60
Vestibular Neurectomy
61
Vestibular Destruction
62
Ultrasound Probe
63
Total Destructive Surgery
Destroys both cochlear & vestibular functions. Done in pt with severe deafness. Types of surgery are: Section of vestibular + cochlear nerves Trans-mastoid total labyrinthectomy
64
Total Destructive Surgery
65
Total Labyrinthectomy
Vestibule + semi-circular canals exposed
66
Total Labyrinthectomy
Vestibule + ampullae opened to show neuro-epithelium
67
Total Labyrinthectomy
Neuro-epithelium destroyed
68
Treatment Ladder
69
Vertigo Control Level Score
Average vertigo spells per month post-treatment (24 mth) = X 100 Average vertigo spells per month pre-treatment (6 mth) Score 0 = Complete control = Level A Score = Substantial control = Level B Score = Limited control = Level C Score = Insignificant control = Level D Score > 120 = Worse = Level E Severe vertigo requiring other treatment = Level F
70
Hearing level reporting
Pure Tone Average taken for 0.5, 1, 2 & 3 KHz If multiple pre and post levels are available, worst is always used PTA is considered improved / worse if a 10 dB difference is noted Speech Discrimination Score is considered improved / worse if a 15% difference is noted
71
Prognosis 60% have complete control of vertigo & 40% have good hearing, without any treatment Medical & surgical therapies show high levels of improvement with placebo Results vary greatly between different series Average result: Level A + B = % Level C = % Level D + E + F = %
72
Thank You
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.